APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Injectables

Compare research editions
View pricing & licenses

Selected research

Industry Research

Sustained Release Injectables Industry Research Report 2026

20 December 2025141 pages

Choose your research edition.

Industry ResearchSustained Release Injectables Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Injectables Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Sustained Release Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Injectables Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Injectables Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Sustained Release Injectables market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Sustained Release Injectables market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sustained Release Injectables market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sustained Release Injectables market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Sustained Release Injectables market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sustained Release Injectables.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Sustained Release Injectables Market by Company

Sanofi

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharm

Eli Lilly

AstraZeneca

Xbrane Biopharma

Taiwan Liposome Company (TLC)

Recipharm AB

PhaseBio Pharmaceuticals

Pacira

OctoPlus

Oakwood Laboratories/PharmaSophia

NanOlogy

Janssen

Ipsen

InnoCore Pharmaceuticals

Enzon

Durect

Critical Pharmaceuticals

Camurus

Biomarin

Avadel

Aurobindo

Ascendis Pharma

AntriaBio

Amylin Pharmaceuticals

Alkermes

Sustained Release Injectables Segment by Type

Gels

Microparticles

Implants

Sustained Release Injectables Segment by Application

Oncology

CNS

Acromegaly

Ophthalmology

Diabetes

Reproductive Health

Rheumatology

Leukemia

Others

Sustained Release Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Sustained Release Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Sustained Release Injectables Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Sustained Release Injectables Revenue Market Share by Type (2021-2026) Table 7. Global Sustained Release Injectables Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Sustained Release Injectables Revenue Market Share by Type (2027-2032) Table 9. Global Sustained Release Injectables Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Sustained Release Injectables Revenue Market Share by Application (2021-2026) Table 11. Global Sustained Release Injectables Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Sustained Release Injectables Revenue Market Share by Application (2027-2032) Table 13. Global Sustained Release Injectables Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Sustained Release Injectables Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Sustained Release Injectables Market Share by Region (2021-2026) Table 16. Global Sustained Release Injectables Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Sustained Release Injectables Market Share by Region (2027-2032) Table 18. Sustained Release Injectables Industry Trends Table 19. Sustained Release Injectables Industry Drivers Table 20. Sustained Release Injectables Industry Opportunities and Challenges Table 21. Sustained Release Injectables Market Restraints Table 22. Global Top Sustained Release Injectables Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Sustained Release Injectables Revenue Market Share by Players (2021-2026) Table 24. Global Sustained Release Injectables Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Sustained Release Injectables, Headquarters and Area Served Table 26. Global Sustained Release Injectables Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Sustained Release Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Sustained Release Injectables Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Sustained Release Injectables Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Sustained Release Injectables Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Sustained Release Injectables Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Sustained Release Injectables Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Sustained Release Injectables Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Sustained Release Injectables Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Sustained Release Injectables Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032) & (US$ Million) Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 48. Sanofi Sustained Release Injectables Product Portfolio Table 49. Sanofi Recent Developments Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 53. Novartis Sustained Release Injectables Product Portfolio Table 54. Novartis Recent Developments Table 55. Merck Company Information Table 56. Merck Business Overview Table 57. Merck Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 58. Merck Sustained Release Injectables Product Portfolio Table 59. Merck Recent Developments Table 60. Luye Pharma Group Company Information Table 61. Luye Pharma Group Business Overview Table 62. Luye Pharma Group Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 63. Luye Pharma Group Sustained Release Injectables Product Portfolio Table 64. Luye Pharma Group Recent Developments Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 68. Roche Sustained Release Injectables Product Portfolio Table 69. Roche Recent Developments Table 70. Livzon Pharm Company Information Table 71. Livzon Pharm Business Overview Table 72. Livzon Pharm Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 73. Livzon Pharm Sustained Release Injectables Product Portfolio Table 74. Livzon Pharm Recent Developments Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 78. Eli Lilly Sustained Release Injectables Product Portfolio Table 79. Eli Lilly Recent Developments Table 80. AstraZeneca Company Information Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 83. AstraZeneca Sustained Release Injectables Product Portfolio Table 84. AstraZeneca Recent Developments Table 85. Xbrane Biopharma Company Information Table 86. Xbrane Biopharma Business Overview Table 87. Xbrane Biopharma Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 88. Xbrane Biopharma Sustained Release Injectables Product Portfolio Table 89. Xbrane Biopharma Recent Developments Table 90. Taiwan Liposome Company (TLC) Company Information Table 91. Taiwan Liposome Company (TLC) Business Overview Table 92. Taiwan Liposome Company (TLC) Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 93. Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio Table 94. Taiwan Liposome Company (TLC) Recent Developments Table 95. Recipharm AB Company Information Table 96. Recipharm AB Business Overview Table 97. Recipharm AB Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 98. Recipharm AB Sustained Release Injectables Product Portfolio Table 99. Recipharm AB Recent Developments Table 100. PhaseBio Pharmaceuticals Company Information Table 101. PhaseBio Pharmaceuticals Business Overview Table 102. PhaseBio Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 103. PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio Table 104. PhaseBio Pharmaceuticals Recent Developments Table 105. Pacira Company Information Table 106. Pacira Business Overview Table 107. Pacira Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 108. Pacira Sustained Release Injectables Product Portfolio Table 109. Pacira Recent Developments Table 110. OctoPlus Company Information Table 111. OctoPlus Business Overview Table 112. OctoPlus Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 113. OctoPlus Sustained Release Injectables Product Portfolio Table 114. OctoPlus Recent Developments Table 115. Oakwood Laboratories/PharmaSophia Company Information Table 116. Oakwood Laboratories/PharmaSophia Business Overview Table 117. Oakwood Laboratories/PharmaSophia Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 118. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio Table 119. Oakwood Laboratories/PharmaSophia Recent Developments Table 120. NanOlogy Company Information Table 121. NanOlogy Business Overview Table 122. NanOlogy Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 123. NanOlogy Sustained Release Injectables Product Portfolio Table 124. NanOlogy Recent Developments Table 125. Janssen Company Information Table 126. Janssen Business Overview Table 127. Janssen Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 128. Janssen Sustained Release Injectables Product Portfolio Table 129. Janssen Recent Developments Table 130. Ipsen Company Information Table 131. Ipsen Business Overview Table 132. Ipsen Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 133. Ipsen Sustained Release Injectables Product Portfolio Table 134. Ipsen Recent Developments Table 135. InnoCore Pharmaceuticals Company Information Table 136. InnoCore Pharmaceuticals Business Overview Table 137. InnoCore Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 138. InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio Table 139. InnoCore Pharmaceuticals Recent Developments Table 140. Enzon Company Information Table 141. Enzon Business Overview Table 142. Enzon Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 143. Enzon Sustained Release Injectables Product Portfolio Table 144. Enzon Recent Developments Table 145. Durect Company Information Table 146. Durect Business Overview Table 147. Durect Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 148. Durect Sustained Release Injectables Product Portfolio Table 149. Durect Recent Developments Table 150. Critical Pharmaceuticals Company Information Table 151. Critical Pharmaceuticals Business Overview Table 152. Critical Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 153. Critical Pharmaceuticals Sustained Release Injectables Product Portfolio Table 154. Critical Pharmaceuticals Recent Developments Table 155. Camurus Company Information Table 156. Camurus Business Overview Table 157. Camurus Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 158. Camurus Sustained Release Injectables Product Portfolio Table 159. Camurus Recent Developments Table 160. Biomarin Company Information Table 161. Biomarin Business Overview Table 162. Biomarin Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 163. Biomarin Sustained Release Injectables Product Portfolio Table 164. Biomarin Recent Developments Table 165. Avadel Company Information Table 166. Avadel Business Overview Table 167. Avadel Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 168. Avadel Sustained Release Injectables Product Portfolio Table 169. Avadel Recent Developments Table 170. Aurobindo Company Information Table 171. Aurobindo Business Overview Table 172. Aurobindo Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 173. Aurobindo Sustained Release Injectables Product Portfolio Table 174. Aurobindo Recent Developments Table 175. Ascendis Pharma Company Information Table 176. Ascendis Pharma Business Overview Table 177. Ascendis Pharma Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 178. Ascendis Pharma Sustained Release Injectables Product Portfolio Table 179. Ascendis Pharma Recent Developments Table 180. AntriaBio Company Information Table 181. AntriaBio Business Overview Table 182. AntriaBio Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 183. AntriaBio Sustained Release Injectables Product Portfolio Table 184. AntriaBio Recent Developments Table 185. Amylin Pharmaceuticals Company Information Table 186. Amylin Pharmaceuticals Business Overview Table 187. Amylin Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 188. Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio Table 189. Amylin Pharmaceuticals Recent Developments Table 190. Alkermes Company Information Table 191. Alkermes Business Overview Table 192. Alkermes Revenue in Sustained Release Injectables Business (2021-2026) & (US$ Million) Table 193. Alkermes Sustained Release Injectables Product Portfolio Table 194. Alkermes Recent Developments Table 195. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Sustained Release Injectables Product Image Figure 5. Global Sustained Release Injectables Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Sustained Release Injectables Market Share by Type: 2025 VS 2032 Figure 7. Gels Product Figure 8. Microparticles Product Figure 9. Implants Product Figure 10. Global Sustained Release Injectables Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sustained Release Injectables Market Share by Application: 2025 VS 2032 Figure 12. Oncology Product Figure 13. CNS Product Figure 14. Acromegaly Product Figure 15. Ophthalmology Product Figure 16. Diabetes Product Figure 17. Reproductive Health Product Figure 18. Rheumatology Product Figure 19. Leukemia Product Figure 20. Others Product Figure 21. Global Sustained Release Injectables Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 22. Global Sustained Release Injectables Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 23. Global Sustained Release Injectables Market Share by Region: 2025 VS 2032 Figure 24. Global Sustained Release Injectables Market Share by Players in 2025 Figure 25. Global Sustained Release Injectables Manufacturers Established Date Figure 26. Global Top 5 and 10 Sustained Release Injectables Players Market Share by Revenue in 2025 Figure 27. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. North America Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Sustained Release Injectables Market Share by Country (2021-2032) Figure 30. United States Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Canada Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Mexico Sustained Release Injectables Market Share by Country (2021-2032) Figure 33. Europe Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Sustained Release Injectables Market Share by Country (2021-2032) Figure 35. Germany Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. France Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. U.K. Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Italy Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Spain Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Russia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Netherlands Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Nordic Countries Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. Asia-Pacific Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia-Pacific Sustained Release Injectables Market Share by Country (2021-2032) Figure 45. China Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Japan Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South Korea Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. India Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. India Sustained Release Injectables Market Share by Country (2021-2032) Figure 50. Australia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. China Taiwan Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Southeast Asia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. South America Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. South America Sustained Release Injectables Market Share by Country (2021-2032) Figure 55. Brazil Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Argentina Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 57. Chile Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 58. Colombia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 59. Peru Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US$ Million) Figure 60. Sanofi Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 61. Novartis Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 62. Merck Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 63. Luye Pharma Group Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 64. Roche Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 65. Livzon Pharm Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 66. Eli Lilly Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 67. AstraZeneca Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 68. Xbrane Biopharma Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 69. Taiwan Liposome Company (TLC) Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 70. Recipharm AB Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 71. PhaseBio Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 72. Pacira Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 73. OctoPlus Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 74. Oakwood Laboratories/PharmaSophia Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 75. NanOlogy Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 76. Janssen Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 77. Ipsen Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 78. InnoCore Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 79. Enzon Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 80. Durect Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 81. Critical Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 82. Camurus Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 83. Biomarin Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 84. Avadel Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 85. Aurobindo Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 86. Ascendis Pharma Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 87. AntriaBio Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 88. Amylin Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026) Figure 89. Alkermes Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)

Scope & coverage.

Types
  • Gels
  • Microparticles
  • Implants
Applications
  • Oncology
  • CNS
  • Acromegaly
  • Ophthalmology
  • Diabetes
  • Reproductive Health
  • Rheumatology
  • Leukemia
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharm
  • Eli Lilly
  • AstraZeneca
  • Xbrane Biopharma
  • Taiwan Liposome Company (TLC)
  • Recipharm AB
  • PhaseBio Pharmaceuticals
  • Pacira
  • OctoPlus
  • Oakwood Laboratories/PharmaSophia
  • NanOlogy
  • Janssen
  • Ipsen
  • InnoCore Pharmaceuticals
  • Enzon
  • Durect
  • Critical Pharmaceuticals
  • Camurus
  • Biomarin
  • Avadel
  • Aurobindo
  • Ascendis Pharma
  • AntriaBio
  • Amylin Pharmaceuticals
  • Alkermes

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Sustained Release Injectables by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Gels
  5. 2.2.3 Microparticles
  6. 2.2.4 Implants
  7. 2.3 Sustained Release Injectables by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 Oncology
  10. 2.3.3 CNS
  11. 2.3.4 Acromegaly
  12. 2.3.5 Ophthalmology
  13. 2.3.6 Diabetes
  14. 2.3.7 Reproductive Health
  15. 2.3.8 Rheumatology
  16. 2.3.9 Leukemia
  17. 2.3.10 Others
  18. 2.4 Assumptions and Limitations
3 Sustained Release Injectables Breakdown Data by Type
  1. 3.1 Global Sustained Release Injectables Historic Market Size by Type (2021-2026)
  2. 3.2 Global Sustained Release Injectables Forecasted Market Size by Type (2027-2032)
4 Sustained Release Injectables Breakdown Data by Application
  1. 4.1 Global Sustained Release Injectables Historic Market Size by Application (2021-2026)
  2. 4.2 Global Sustained Release Injectables Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Sustained Release Injectables Market Perspective (2021-2032)
  2. 5.2 Global Sustained Release Injectables Growth Trends by Region
  3. 5.2.1 Global Sustained Release Injectables Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Sustained Release Injectables Historic Market Size by Region (2021-2026)
  5. 5.2.3 Sustained Release Injectables Forecasted Market Size by Region (2027-2032)
  6. 5.3 Sustained Release Injectables Market Dynamics
  7. 5.3.1 Sustained Release Injectables Industry Trends
  8. 5.3.2 Sustained Release Injectables Market Drivers
  9. 5.3.3 Sustained Release Injectables Market Challenges
  10. 5.3.4 Sustained Release Injectables Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Sustained Release Injectables Players by Revenue
  2. 6.1.1 Global Top Sustained Release Injectables Players by Revenue (2021-2026)
  3. 6.1.2 Global Sustained Release Injectables Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Sustained Release Injectables Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Sustained Release Injectables Head Office and Area Served
  6. 6.4 Global Sustained Release Injectables Players, Product Type & Application
  7. 6.5 Global Sustained Release Injectables Manufacturers Established Date
  8. 6.6 Global Sustained Release Injectables Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Sustained Release Injectables Market Size (2021-2032)
  2. 7.2 North America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Sustained Release Injectables Market Size by Country (2021-2026)
  4. 7.4 North America Sustained Release Injectables Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Sustained Release Injectables Market Size (2021-2032)
  2. 8.2 Europe Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Sustained Release Injectables Market Size by Country (2021-2026)
  4. 8.4 Europe Sustained Release Injectables Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Sustained Release Injectables Market Size (2021-2032)
  2. 9.2 Asia-Pacific Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Sustained Release Injectables Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Sustained Release Injectables Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Sustained Release Injectables Market Size (2021-2032)
  2. 10.2 South America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Sustained Release Injectables Market Size by Country (2021-2026)
  4. 10.4 South America Sustained Release Injectables Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Sustained Release Injectables Market Size (2021-2032)
  2. 11.2 Middle East & Africa Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Sanofi
  2. 12.1.1 Sanofi Company Information
  3. 12.1.2 Sanofi Business Overview
  4. 12.1.3 Sanofi Revenue in Sustained Release Injectables Business (2021-2026)
  5. 12.1.4 Sanofi Sustained Release Injectables Product Portfolio
  6. 12.1.5 Sanofi Recent Developments
  7. 12.2 Novartis
  8. 12.2.1 Novartis Company Information
  9. 12.2.2 Novartis Business Overview
  10. 12.2.3 Novartis Revenue in Sustained Release Injectables Business (2021-2026)
  11. 12.2.4 Novartis Sustained Release Injectables Product Portfolio
  12. 12.2.5 Novartis Recent Developments
  13. 12.3 Merck
  14. 12.3.1 Merck Company Information
  15. 12.3.2 Merck Business Overview
  16. 12.3.3 Merck Revenue in Sustained Release Injectables Business (2021-2026)
  17. 12.3.4 Merck Sustained Release Injectables Product Portfolio
  18. 12.3.5 Merck Recent Developments
  19. 12.4 Luye Pharma Group
  20. 12.4.1 Luye Pharma Group Company Information
  21. 12.4.2 Luye Pharma Group Business Overview
  22. 12.4.3 Luye Pharma Group Revenue in Sustained Release Injectables Business (2021-2026)
  23. 12.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
  24. 12.4.5 Luye Pharma Group Recent Developments
  25. 12.5 Roche
  26. 12.5.1 Roche Company Information
  27. 12.5.2 Roche Business Overview
  28. 12.5.3 Roche Revenue in Sustained Release Injectables Business (2021-2026)
  29. 12.5.4 Roche Sustained Release Injectables Product Portfolio
  30. 12.5.5 Roche Recent Developments
  31. 12.6 Livzon Pharm
  32. 12.6.1 Livzon Pharm Company Information
  33. 12.6.2 Livzon Pharm Business Overview
  34. 12.6.3 Livzon Pharm Revenue in Sustained Release Injectables Business (2021-2026)
  35. 12.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
  36. 12.6.5 Livzon Pharm Recent Developments
  37. 12.7 Eli Lilly
  38. 12.7.1 Eli Lilly Company Information
  39. 12.7.2 Eli Lilly Business Overview
  40. 12.7.3 Eli Lilly Revenue in Sustained Release Injectables Business (2021-2026)
  41. 12.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
  42. 12.7.5 Eli Lilly Recent Developments
  43. 12.8 AstraZeneca
  44. 12.8.1 AstraZeneca Company Information
  45. 12.8.2 AstraZeneca Business Overview
  46. 12.8.3 AstraZeneca Revenue in Sustained Release Injectables Business (2021-2026)
  47. 12.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
  48. 12.8.5 AstraZeneca Recent Developments
  49. 12.9 Xbrane Biopharma
  50. 12.9.1 Xbrane Biopharma Company Information
  51. 12.9.2 Xbrane Biopharma Business Overview
  52. 12.9.3 Xbrane Biopharma Revenue in Sustained Release Injectables Business (2021-2026)
  53. 12.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
  54. 12.9.5 Xbrane Biopharma Recent Developments
  55. 12.10 Taiwan Liposome Company (TLC)
  56. 12.10.1 Taiwan Liposome Company (TLC) Company Information
  57. 12.10.2 Taiwan Liposome Company (TLC) Business Overview
  58. 12.10.3 Taiwan Liposome Company (TLC) Revenue in Sustained Release Injectables Business (2021-2026)
  59. 12.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
  60. 12.10.5 Taiwan Liposome Company (TLC) Recent Developments
  61. 12.11 Recipharm AB
  62. 12.11.1 Recipharm AB Company Information
  63. 12.11.2 Recipharm AB Business Overview
  64. 12.11.3 Recipharm AB Revenue in Sustained Release Injectables Business (2021-2026)
  65. 12.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
  66. 12.11.5 Recipharm AB Recent Developments
  67. 12.12 PhaseBio Pharmaceuticals
  68. 12.12.1 PhaseBio Pharmaceuticals Company Information
  69. 12.12.2 PhaseBio Pharmaceuticals Business Overview
  70. 12.12.3 PhaseBio Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
  71. 12.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
  72. 12.12.5 PhaseBio Pharmaceuticals Recent Developments
  73. 12.13 Pacira
  74. 12.13.1 Pacira Company Information
  75. 12.13.2 Pacira Business Overview
  76. 12.13.3 Pacira Revenue in Sustained Release Injectables Business (2021-2026)
  77. 12.13.4 Pacira Sustained Release Injectables Product Portfolio
  78. 12.13.5 Pacira Recent Developments
  79. 12.14 OctoPlus
  80. 12.14.1 OctoPlus Company Information
  81. 12.14.2 OctoPlus Business Overview
  82. 12.14.3 OctoPlus Revenue in Sustained Release Injectables Business (2021-2026)
  83. 12.14.4 OctoPlus Sustained Release Injectables Product Portfolio
  84. 12.14.5 OctoPlus Recent Developments
  85. 12.15 Oakwood Laboratories/PharmaSophia
  86. 12.15.1 Oakwood Laboratories/PharmaSophia Company Information
  87. 12.15.2 Oakwood Laboratories/PharmaSophia Business Overview
  88. 12.15.3 Oakwood Laboratories/PharmaSophia Revenue in Sustained Release Injectables Business (2021-2026)
  89. 12.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
  90. 12.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
  91. 12.16 NanOlogy
  92. 12.16.1 NanOlogy Company Information
  93. 12.16.2 NanOlogy Business Overview
  94. 12.16.3 NanOlogy Revenue in Sustained Release Injectables Business (2021-2026)
  95. 12.16.4 NanOlogy Sustained Release Injectables Product Portfolio
  96. 12.16.5 NanOlogy Recent Developments
  97. 12.17 Janssen
  98. 12.17.1 Janssen Company Information
  99. 12.17.2 Janssen Business Overview
  100. 12.17.3 Janssen Revenue in Sustained Release Injectables Business (2021-2026)
  101. 12.17.4 Janssen Sustained Release Injectables Product Portfolio
  102. 12.17.5 Janssen Recent Developments
  103. 12.18 Ipsen
  104. 12.18.1 Ipsen Company Information
  105. 12.18.2 Ipsen Business Overview
  106. 12.18.3 Ipsen Revenue in Sustained Release Injectables Business (2021-2026)
  107. 12.18.4 Ipsen Sustained Release Injectables Product Portfolio
  108. 12.18.5 Ipsen Recent Developments
  109. 12.19 InnoCore Pharmaceuticals
  110. 12.19.1 InnoCore Pharmaceuticals Company Information
  111. 12.19.2 InnoCore Pharmaceuticals Business Overview
  112. 12.19.3 InnoCore Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
  113. 12.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
  114. 12.19.5 InnoCore Pharmaceuticals Recent Developments
  115. 12.20 Enzon
  116. 12.20.1 Enzon Company Information
  117. 12.20.2 Enzon Business Overview
  118. 12.20.3 Enzon Revenue in Sustained Release Injectables Business (2021-2026)
  119. 12.20.4 Enzon Sustained Release Injectables Product Portfolio
  120. 12.20.5 Enzon Recent Developments
  121. 12.21 Durect
  122. 12.21.1 Durect Company Information
  123. 12.21.2 Durect Business Overview
  124. 12.21.3 Durect Revenue in Sustained Release Injectables Business (2021-2026)
  125. 12.21.4 Durect Sustained Release Injectables Product Portfolio
  126. 12.21.5 Durect Recent Developments
  127. 12.22 Critical Pharmaceuticals
  128. 12.22.1 Critical Pharmaceuticals Company Information
  129. 12.22.2 Critical Pharmaceuticals Business Overview
  130. 12.22.3 Critical Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
  131. 12.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
  132. 12.22.5 Critical Pharmaceuticals Recent Developments
  133. 12.23 Camurus
  134. 12.23.1 Camurus Company Information
  135. 12.23.2 Camurus Business Overview
  136. 12.23.3 Camurus Revenue in Sustained Release Injectables Business (2021-2026)
  137. 12.23.4 Camurus Sustained Release Injectables Product Portfolio
  138. 12.23.5 Camurus Recent Developments
  139. 12.24 Biomarin
  140. 12.24.1 Biomarin Company Information
  141. 12.24.2 Biomarin Business Overview
  142. 12.24.3 Biomarin Revenue in Sustained Release Injectables Business (2021-2026)
  143. 12.24.4 Biomarin Sustained Release Injectables Product Portfolio
  144. 12.24.5 Biomarin Recent Developments
  145. 12.25 Avadel
  146. 12.25.1 Avadel Company Information
  147. 12.25.2 Avadel Business Overview
  148. 12.25.3 Avadel Revenue in Sustained Release Injectables Business (2021-2026)
  149. 12.25.4 Avadel Sustained Release Injectables Product Portfolio
  150. 12.25.5 Avadel Recent Developments
  151. 12.26 Aurobindo
  152. 12.26.1 Aurobindo Company Information
  153. 12.26.2 Aurobindo Business Overview
  154. 12.26.3 Aurobindo Revenue in Sustained Release Injectables Business (2021-2026)
  155. 12.26.4 Aurobindo Sustained Release Injectables Product Portfolio
  156. 12.26.5 Aurobindo Recent Developments
  157. 12.27 Ascendis Pharma
  158. 12.27.1 Ascendis Pharma Company Information
  159. 12.27.2 Ascendis Pharma Business Overview
  160. 12.27.3 Ascendis Pharma Revenue in Sustained Release Injectables Business (2021-2026)
  161. 12.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
  162. 12.27.5 Ascendis Pharma Recent Developments
  163. 12.28 AntriaBio
  164. 12.28.1 AntriaBio Company Information
  165. 12.28.2 AntriaBio Business Overview
  166. 12.28.3 AntriaBio Revenue in Sustained Release Injectables Business (2021-2026)
  167. 12.28.4 AntriaBio Sustained Release Injectables Product Portfolio
  168. 12.28.5 AntriaBio Recent Developments
  169. 12.29 Amylin Pharmaceuticals
  170. 12.29.1 Amylin Pharmaceuticals Company Information
  171. 12.29.2 Amylin Pharmaceuticals Business Overview
  172. 12.29.3 Amylin Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
  173. 12.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
  174. 12.29.5 Amylin Pharmaceuticals Recent Developments
  175. 12.30 Alkermes
  176. 12.30.1 Alkermes Company Information
  177. 12.30.2 Alkermes Business Overview
  178. 12.30.3 Alkermes Revenue in Sustained Release Injectables Business (2021-2026)
  179. 12.30.4 Alkermes Sustained Release Injectables Product Portfolio
  180. 12.30.5 Alkermes Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst